AKT1 and neoplasm: In cancer development, the PI3K-AKT-mTOR pathway is hyperactivated due to mutations in PI3K, AKT, or mTOR or loss of the tumour suppressor PTEN, contributing to uncontrolled growth and therapy resistance [60,61,62].